Niraxx Light Therapeutics Announces Initiation of a Phase 2 Depression Clinical Trial

[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] “We think the device’s wearability—ability to deliver treatment whenever and wherever—will change the care paradigm for depression.” [/et_pb_text][et_pb_text _builder_version=”4.4.5″ text_font=”Vollkorn||||||||” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone”] Irvine, Calif. — Niraxx Light Therapeutics, a leader in wearable neurotechnology, today announced the initiation of a […]

We are our brains: A Beginner’s Guide to Neuromodulation

[et_pb_section fb_built=”1″ use_custom_gutter=”on” specialty=”on” parallax_method_1=”off” parallax_method_2=”off” module_class=”m-special-section-modifier et_pb_specialty_fullwidth” _builder_version=”3.22″ inner_width=”89%” inner_width_tablet=”80%” inner_width_phone=”” inner_width_last_edited=”on|desktop” inner_max_width=”89%” inner_max_width_tablet=”80%” inner_max_width_phone=”” inner_max_width_last_edited=”on|desktop” custom_padding=”|||” transparent_background=”off” make_fullwidth=”on”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_row_inner admin_label=”Row” _builder_version=”3.25″][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Post content” _builder_version=”4.4.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|desktop” use_border_color=”off”] The brain is one of the most complicated and intricate systems that […]

Research | tPBM Improves Cognitive Performance in Healthy Brains

Research show t-PBM has a significant, beneficial effect on cognitive performance in young, healthy adults. Nine studies were examined, of which seven studies were performed on young, health subjects ages 17-24 and two were conducted on older normal subjects ages 49 and up.

Shining Light on Depression, a New Approach to Treatment

Depression is estimated to affect 300 million people globally. Antidepressant medication is the first-line treatment for depression, but what about people who did not respond to or want to take medication? New research findings suggest light therapy offers new approach to treating depression.

Research | tPBM for the Treatment of Major Depressive Disorder, Elated 2

This paper reports the results from the Elated-2 Pilot Trial. The study is comprised of 21 adult MDD patients age 18 to 65, who underwent twice weekly transcranial photobiomodulation (t-BPM) sessions for 8 weeks. The study finds subjects receiving t-PBM with NIR light showed greater improvement than the sham group that did not receive any light therapy.

Research | tPBM for the Management of Depression: Current Perspectives

Current treatments for depression have significant efficacy and side effect burden. This paper provides a comprehensive overview of years of research on a novel, safe approach called transcranial photobiomodulation (t-PBM) as a device-based treatment that is efficacious, well-tolerated and easy to use.